Literature DB >> 28662292

Benign and malignant tumors in the UK myotonic dystrophy patient registry.

Rotana Alsaggaf1,2, Youjin Wang1, Chiara Marini-Bettolo3, Libby Wood3, Nikoletta Nikolenko3, Hanns Lochmüller3, Mark H Greene1, Shahinaz M Gadalla1.   

Abstract

INTRODUCTION: In light of recent evidence indicating that cancer is part of the myotonic dystrophy (DM) phenotype, we assessed the prevalence of benign and malignant tumors among 220 patients enrolled in the UK Myotonic Dystrophy Patient Registry and evaluated factors associated with their development.
METHODS: A survey was distributed to collect tumor history and lifestyle information. We used multinomial logistic regression for the analysis.
RESULTS: Thirty-nine benign (30 patients), and 16 malignant (15 patients) tumors were reported. Increasing age (odds ratio [OR] = 1.13, 95% confidence interval [CI] = 1.05-1.21, P = 0.001) and earlier age at DM diagnosis (OR = 1.06, 95% CI = 1.00-1.13, P = 0.04) were associated with benign and malignant tumors (OR = 1.20, 95% CI = 1.10-1.30, P < 0.001 and OR = 1.08, 95% CI = 1.01-1.15, P = 0.02, respectively). Female gender was associated with benign tumors only (OR = 6.43, 95% CI = 1.79-23.04, P = 0.004). No associations were observed between tumors and smoking (P = 0.24), alcohol consumption (P = 0.50), or body mass index (P = 0.21). DISCUSSION: Our results confirm previous findings suggesting a limited role for common lifestyle factors and a potential genetic contribution in DM tumor predisposition. Muscle Nerve 57: 316-320, 2018.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer; lifestyle factors; myotonic dystrophy; risk factors; smoking; tumor

Mesh:

Year:  2017        PMID: 28662292      PMCID: PMC7188193          DOI: 10.1002/mus.25736

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  20 in total

1.  Cancer risk among patients with myotonic muscular dystrophy.

Authors:  Shahinaz M Gadalla; Marie Lund; Ruth M Pfeiffer; Sanne Gørtz; Christine M Mueller; Richard T Moxley; Sigurdur Y Kristinsson; Magnus Björkholm; Fatma M Shebl; James E Hilbert; Ola Landgren; Jan Wohlfahrt; Mads Melbye; Mark H Greene
Journal:  JAMA       Date:  2011-12-14       Impact factor: 56.272

2.  Validity of self-reported cancer history: a comparison of health interview data and cancer registry records.

Authors:  M M Desai; M L Bruce; R A Desai; B G Druss
Journal:  Am J Epidemiol       Date:  2001-02-01       Impact factor: 4.897

Review 3.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

4.  Correlates of tumor development in patients with myotonic dystrophy.

Authors:  Maya Das; Richard T Moxley; James E Hilbert; William B Martens; Lisa Letren; Mark H Greene; Shahinaz M Gadalla
Journal:  J Neurol       Date:  2012-05-23       Impact factor: 4.849

5.  Cancer risk in DM1 is sex-related and linked to miRNA-200/141 downregulation.

Authors:  Roberto Fernández-Torrón; Mikel García-Puga; José-Ignacio Emparanza; Miren Maneiro; Ana-María Cobo; Juan-José Poza; Juan-Bautista Espinal; Miren Zulaica; Irune Ruiz; Loreto Martorell; David Otaegui; Ander Matheu; Adolfo López de Munain
Journal:  Neurology       Date:  2016-08-24       Impact factor: 9.910

6.  Validity of self-reported cancers in a prospective cohort study in comparison with data from state cancer registries.

Authors:  M M Bergmann; E E Calle; C A Mervis; H L Miracle-McMahill; M J Thun; C W Heath
Journal:  Am J Epidemiol       Date:  1998-03-15       Impact factor: 4.897

Review 7.  Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.

Authors:  Laura P W Ranum; John W Day
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

8.  Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors.

Authors:  Maria Laura Ester Bianchi; Emanuele Leoncini; Marcella Masciullo; Anna Modoni; Shahinaz M Gadalla; Roberto Massa; Emanuele Rastelli; Chiara Terracciano; Giovanni Antonini; Elisabetta Bucci; Antonio Petrucci; Sandro Costanzi; Massimo Santoro; Stefania Boccia; Gabriella Silvestri
Journal:  J Neurol       Date:  2016-01-06       Impact factor: 4.849

9.  A population-based survey of risk for cancer in individuals diagnosed with myotonic dystrophy.

Authors:  Diana Abbott; Nicholas E Johnson; Lisa A Cannon-Albright
Journal:  Muscle Nerve       Date:  2016-07-07       Impact factor: 3.217

10.  The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research.

Authors:  Libby Wood; Isabell Cordts; Antonio Atalaia; Chiara Marini-Bettolo; Paul Maddison; Margaret Phillips; Mark Roberts; Mark Rogers; Simon Hammans; Volker Straub; Richard Petty; Richard Orrell; Darren G Monckton; Nikoletta Nikolenko; Aura Cecilia Jimenez-Moreno; Rachel Thompson; David Hilton-Jones; Chris Turner; Hanns Lochmüller
Journal:  J Neurol       Date:  2017-04-10       Impact factor: 4.849

View more
  8 in total

1.  Cancer phenotype in myotonic dystrophy patients: Results from a meta-analysis.

Authors:  Jose I Emparanza; Adolfo López de Munain; Mark H Greene; Ander Matheu; Roberto Fernández-Torrón; Shahinaz M Gadalla
Journal:  Muscle Nerve       Date:  2018-10       Impact factor: 3.217

2.  Survival patterns and cancer determinants in families with myotonic dystrophy type 1.

Authors:  A F Best; J E Hilbert; L Wood; W B Martens; N Nikolenko; C Marini-Bettolo; H Lochmüller; P S Rosenberg; R T Moxley; M H Greene; S M Gadalla
Journal:  Eur J Neurol       Date:  2018-09-16       Impact factor: 6.089

3.  Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink.

Authors:  Youjin Wang; Ruth M Pfeiffer; Rotana Alsaggaf; Wilhelmine Meeraus; Julia C Gage; Lesley A Anderson; Renée C Bremer; Nikoletta Nikolenko; Hanns Lochmuller; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2017-11-20       Impact factor: 7.396

4.  Reproductive Cancer Risk Factors in Women With Myotonic Dystrophy (DM): Survey Data From the US and UK DM Registries.

Authors:  Cecilia Higgs; James E Hilbert; Libby Wood; William B Martens; Chiara Marini-Bettolo; Nikoletta Nikolenko; Rotana Alsaggaf; Hanns Lochmüller; Richard T Moxley; Mark H Greene; Youjin Wang; Shahinaz M Gadalla
Journal:  Front Neurol       Date:  2019-10-11       Impact factor: 4.003

5.  Benign tumors in myotonic dystrophy type I target disease-related cancer sites.

Authors:  Rotana Alsaggaf; Diane Marie M St George; Min Zhan; Ruth M Pfeiffer; Youjin Wang; Lesley A Anderson; Zhiwei Liu; Jill Koshiol; Andrew J Bauer; Kathryn R Wagner; Mark H Greene; Sania Amr; Shahinaz M Gadalla
Journal:  Ann Clin Transl Neurol       Date:  2019-07-26       Impact factor: 4.511

6.  Reliability of the application of transvaginal color Doppler ultrasound in the identification of pelvic tumors in women of childbearing age.

Authors:  Mingchun Zhi; Miaoqian Wang; Wei Li; Lijie Ma; Qian Liu; Ye Li; Qiubo Lv
Journal:  Ann Transl Med       Date:  2020-12

7.  Cutaneous findings in myotonic dystrophy.

Authors:  Ha Eun Kong; Brian P Pollack
Journal:  JAAD Int       Date:  2022-02-22

Review 8.  Core Clinical Phenotypes in Myotonic Dystrophies.

Authors:  Stephan Wenninger; Federica Montagnese; Benedikt Schoser
Journal:  Front Neurol       Date:  2018-05-02       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.